Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.

with disappointing data for phase 2 drug monlunabant in September and phase 3 GLP-1 and amylin combination cagrisema in December. Novo and Lilly are fighting for share in the global GLP-1 market ...

The year-over-year increase in revenues was driven by higher Diabetes and Obesity Care sales as GLP-1 product sales ... with the industry’s 3.1% decline. Image Source: Zacks Investment Research ...